Canis familiaris (dog)
| UniProt ID | Protein Name | Gene Symbol | No. of Glycosylation Sites | No. of GlyTouCan IDs | Disease Ontology |
|---|---|---|---|---|---|
| A0A8C0RHV4 | Angiotensin-converting enzyme |
|
11 | 0 |
|
| P33729 | Intercellular adhesion molecule 1 (Fragment) |
|
11 | 0 |
|
| P32750 | Cholinesterase (Fragment) |
|
1 | 0 |
|
| A0A8P0SDL0 | ADAM metallopeptidase with thrombospondin type 1 motif 5 |
|
2 | 0 |
|
| A0A8C0T8N5 | Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase |
|
1 | 0 |
|
| Q95MM9 | Signaling lymphocytic activation molecule |
|
7 | 0 |
|
| A0A8C0NPV7 | Paraoxonase 3 |
|
2 | 0 |
|
| P54833 | Beta-2 adrenergic receptor |
|
2 | 0 |
|
| A0A8C0TUF8 | Voltage-dependent L-type calcium channel subunit alpha |
|
1 | 0 |
|
| Q28279 | Cyclic nucleotide-gated channel alpha-1 |
|
1 | 0 |
|
| Q9MZI6 | Gonadotropin-releasing hormone receptor |
|
2 | 0 |
|
| Q9TSZ6 | Dystroglycan 1 |
|
7 | 0 |
|
| P0CAN6 | B-cell antigen receptor complex-associated protein alpha chain |
|
2 | 0 |
|
| E2RQ08 | Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 |
|
1 | 0 |
|
| A0A8I3N115 | Hyaluronidase |
|
1 | 0 |
|
| A0A8C0TV81 | GDNF family receptor alpha |
|
2 | 0 |
|
| P30552 | Gastrin/cholecystokinin type B receptor |
|
3 | 0 |
|
| P11614 | 5-hydroxytryptamine receptor 1D |
|
3 | 0 |
|
| P54804 | Galactocerebrosidase |
|
4 | 0 |
|
| Q9TSZ3 | Voltage-gated inwardly rectifying potassium channel KCNH2 |
|
1 | 0 |
|
| Q6UKZ8 | Growth/differentiation factor 8 |
|
1 | 0 |
|
| Q6UKI2 | Protein amnionless |
|
1 | 0 |
|
| A0A8C0RUQ1 | L-selectin |
|
3 | 0 |
|
| Q5DUB3 | Substance-P receptor |
|
2 | 0 |
|
| A0A8C0PQ06 | Protein adenylyltransferase FICD |
|
1 | 0 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025